Clinical Trials
30 trialsBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
UPCC 25406
Abramson Cancer Center at Penn Medicine
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
Mayo Clinic
PLX3397
Columbia University
PROSKIN
Charite University, Berlin, Germany
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Emory University
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
Albert Einstein College of Medicine
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Aging Mammary Stem Cells and Breast Cancer Prevention
The University of Texas Health Science Center at San Antonio
A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
Boston Children's Hospital
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of Washington
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
SIR-MO-1101
Children's Hospital Medical Center, Cincinnati
BEZ235
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
University of Texas Southwestern Medical Center
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
Indiana University
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Stanford University
PROSKIN
University Hospital of Berlin
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
Shin Kong Wu Ho-Su Memorial Hospital
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
The Korean Society of Blood and Marrow Transplantation
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
Children's Hospital of Philadelphia
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
Yale University
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
Yale University
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center